Global Branded Generics

Branded Generics Comprehensive Study by Type (Value Added Branded Generics, Trade (Brand) Named Generics), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores, Others), Formulation Type (Oral, Parenteral, Topical, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Branded Generics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
A branded generic is a generic drug that has been given a name rather than the chemical name after going through the ANDA phase. After a patent expires, these branded generic drugs may be manufactured by a generic drug company or by the original manufacturer. The increase in the number of expired patents is the primary driver of the growth of branded generics. A rise in the number of patients with chronic and acute illnesses necessitates the use of marketed generics. Furthermore, in their search for low-cost, reliable pharmaceuticals, they become aware of the idea of branded generics. As a result, the branded generics market's growth potential is expanding. Cardiac arrests, diabetes, and hypertension account for a large percentage of all deaths worldwide. Anti-hypertensive medications have been in high demand from all over the world. This necessitates the use of cost-effective medications, and branded generics have proved to be a viable option.This growth is primarily driven by Increasing Demand For Anti-Hypertensive Drugs.

Globally, a noticeable market trend is evident Recent Relaxations Granted by the Aforementioned Authorities. Major Players, such as Mylan N.V (United States), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), Aspen Pharmacare (South Africa), Abbott Laboratories (United States), Valeant Pharmaceuticals International, Inc. (Canada), Sanofi (France) and GlaxoSmithKline Pharmaceuticals (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

January 2020 – Greenstone, a wholly owned subsidiary of Pfizer Inc., announced a supply agreement with Roman, an innovative digital healthcare clinic, to offer Roman members access to the only FDA-approved authorized generic version of Viagra (sildenafil citrate).

Regulatory Insights:
In the U.S Federal Food Drugs and Cosmetics Act (FD&C Act) and Controlled Substances Act, or CSA govern all the activities related to branded generics including development, manufacturing, testing, labelling, distribution, advertising & promotion, sales, import export of generic products. The manufacturer of branded generic products required to obtain abbreviated new drug application (ANDA) approval under section 505(b)(2) of Federal Food Drug and Cosmetics Act

Market Drivers
  • Increasing Demand For Anti-Hypertensive Drugs

Market Trend
  • Recent Relaxations Granted by the Aforementioned Authorities

Restraints
  • Misapplication of Risk Evaluation and Mitigation Strategies (REMS) To Delay Generic Market Entry

Opportunities
Growing Number Of Patents Expired And Expiring For Branded Drugs and Simple Marketing Authorization Procedures, Changing Medicine Practices, Greater Profit Margin
Challenges
Various Regulations Need To Be Followed and Complications In Getting License For Certain Products

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Branded Generics Study Sheds Light on
— The Branded Generics Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Branded Generics industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Branded Generics industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Value Added Branded Generics
  • Trade (Brand) Named Generics
By Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores
  • Others
By Formulation Type
  • Oral
  • Parenteral
  • Topical
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand For Anti-Hypertensive Drugs
    • 3.3. Market Challenges
      • 3.3.1. Various Regulations Need To Be Followed
      • 3.3.2. Complications In Getting License For Certain Products
    • 3.4. Market Trends
      • 3.4.1. Recent Relaxations Granted by the Aforementioned Authorities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Branded Generics, by Type, Application, Formulation Type, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Branded Generics (Value)
      • 5.2.1. Global Branded Generics by: Type (Value)
        • 5.2.1.1. Value Added Branded Generics
        • 5.2.1.2. Trade (Brand) Named Generics
      • 5.2.2. Global Branded Generics by: Application (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
        • 5.2.2.4. Drug Stores
        • 5.2.2.5. Others
      • 5.2.3. Global Branded Generics by: Formulation Type (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
        • 5.2.3.3. Topical
        • 5.2.3.4. Others
      • 5.2.4. Global Branded Generics by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Branded Generics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Branded Generics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Mylan N.V (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Aspen Pharmacare (South Africa)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbott Laboratories (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Valeant Pharmaceuticals International, Inc. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GlaxoSmithKline Pharmaceuticals (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Branded Generics Sale, by Type, Application, Formulation Type, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Branded Generics (Value)
      • 7.2.1. Global Branded Generics by: Type (Value)
        • 7.2.1.1. Value Added Branded Generics
        • 7.2.1.2. Trade (Brand) Named Generics
      • 7.2.2. Global Branded Generics by: Application (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
        • 7.2.2.4. Drug Stores
        • 7.2.2.5. Others
      • 7.2.3. Global Branded Generics by: Formulation Type (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
        • 7.2.3.3. Topical
        • 7.2.3.4. Others
      • 7.2.4. Global Branded Generics by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Branded Generics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Branded Generics: by Type(USD Million)
  • Table 2. Branded Generics Value Added Branded Generics , by Region USD Million (2015-2020)
  • Table 3. Branded Generics Trade (Brand) Named Generics , by Region USD Million (2015-2020)
  • Table 4. Branded Generics: by Application(USD Million)
  • Table 5. Branded Generics Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 6. Branded Generics Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Branded Generics Online Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Branded Generics Drug Stores , by Region USD Million (2015-2020)
  • Table 9. Branded Generics Others , by Region USD Million (2015-2020)
  • Table 10. Branded Generics: by Formulation Type(USD Million)
  • Table 11. Branded Generics Oral , by Region USD Million (2015-2020)
  • Table 12. Branded Generics Parenteral , by Region USD Million (2015-2020)
  • Table 13. Branded Generics Topical , by Region USD Million (2015-2020)
  • Table 14. Branded Generics Others , by Region USD Million (2015-2020)
  • Table 15. Branded Generics: by Distribution Channel(USD Million)
  • Table 16. Branded Generics Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 17. Branded Generics Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 18. Branded Generics Online Pharmacies , by Region USD Million (2015-2020)
  • Table 19. South America Branded Generics, by Country USD Million (2015-2020)
  • Table 20. South America Branded Generics, by Type USD Million (2015-2020)
  • Table 21. South America Branded Generics, by Application USD Million (2015-2020)
  • Table 22. South America Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 23. South America Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 24. Brazil Branded Generics, by Type USD Million (2015-2020)
  • Table 25. Brazil Branded Generics, by Application USD Million (2015-2020)
  • Table 26. Brazil Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 27. Brazil Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 28. Argentina Branded Generics, by Type USD Million (2015-2020)
  • Table 29. Argentina Branded Generics, by Application USD Million (2015-2020)
  • Table 30. Argentina Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 31. Argentina Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 32. Rest of South America Branded Generics, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Branded Generics, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 35. Rest of South America Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 36. Asia Pacific Branded Generics, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Branded Generics, by Type USD Million (2015-2020)
  • Table 38. Asia Pacific Branded Generics, by Application USD Million (2015-2020)
  • Table 39. Asia Pacific Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 40. Asia Pacific Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 41. China Branded Generics, by Type USD Million (2015-2020)
  • Table 42. China Branded Generics, by Application USD Million (2015-2020)
  • Table 43. China Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 44. China Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 45. Japan Branded Generics, by Type USD Million (2015-2020)
  • Table 46. Japan Branded Generics, by Application USD Million (2015-2020)
  • Table 47. Japan Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 48. Japan Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 49. India Branded Generics, by Type USD Million (2015-2020)
  • Table 50. India Branded Generics, by Application USD Million (2015-2020)
  • Table 51. India Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 52. India Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 53. South Korea Branded Generics, by Type USD Million (2015-2020)
  • Table 54. South Korea Branded Generics, by Application USD Million (2015-2020)
  • Table 55. South Korea Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 56. South Korea Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 57. Taiwan Branded Generics, by Type USD Million (2015-2020)
  • Table 58. Taiwan Branded Generics, by Application USD Million (2015-2020)
  • Table 59. Taiwan Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 60. Taiwan Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 61. Australia Branded Generics, by Type USD Million (2015-2020)
  • Table 62. Australia Branded Generics, by Application USD Million (2015-2020)
  • Table 63. Australia Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 64. Australia Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Branded Generics, by Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Branded Generics, by Application USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 69. Europe Branded Generics, by Country USD Million (2015-2020)
  • Table 70. Europe Branded Generics, by Type USD Million (2015-2020)
  • Table 71. Europe Branded Generics, by Application USD Million (2015-2020)
  • Table 72. Europe Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 73. Europe Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 74. Germany Branded Generics, by Type USD Million (2015-2020)
  • Table 75. Germany Branded Generics, by Application USD Million (2015-2020)
  • Table 76. Germany Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 77. Germany Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 78. France Branded Generics, by Type USD Million (2015-2020)
  • Table 79. France Branded Generics, by Application USD Million (2015-2020)
  • Table 80. France Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 81. France Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 82. Italy Branded Generics, by Type USD Million (2015-2020)
  • Table 83. Italy Branded Generics, by Application USD Million (2015-2020)
  • Table 84. Italy Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 85. Italy Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 86. United Kingdom Branded Generics, by Type USD Million (2015-2020)
  • Table 87. United Kingdom Branded Generics, by Application USD Million (2015-2020)
  • Table 88. United Kingdom Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 89. United Kingdom Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 90. Netherlands Branded Generics, by Type USD Million (2015-2020)
  • Table 91. Netherlands Branded Generics, by Application USD Million (2015-2020)
  • Table 92. Netherlands Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 93. Netherlands Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 94. Rest of Europe Branded Generics, by Type USD Million (2015-2020)
  • Table 95. Rest of Europe Branded Generics, by Application USD Million (2015-2020)
  • Table 96. Rest of Europe Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 97. Rest of Europe Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 98. MEA Branded Generics, by Country USD Million (2015-2020)
  • Table 99. MEA Branded Generics, by Type USD Million (2015-2020)
  • Table 100. MEA Branded Generics, by Application USD Million (2015-2020)
  • Table 101. MEA Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 102. MEA Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 103. Middle East Branded Generics, by Type USD Million (2015-2020)
  • Table 104. Middle East Branded Generics, by Application USD Million (2015-2020)
  • Table 105. Middle East Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 106. Middle East Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 107. Africa Branded Generics, by Type USD Million (2015-2020)
  • Table 108. Africa Branded Generics, by Application USD Million (2015-2020)
  • Table 109. Africa Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 110. Africa Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 111. North America Branded Generics, by Country USD Million (2015-2020)
  • Table 112. North America Branded Generics, by Type USD Million (2015-2020)
  • Table 113. North America Branded Generics, by Application USD Million (2015-2020)
  • Table 114. North America Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 115. North America Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 116. United States Branded Generics, by Type USD Million (2015-2020)
  • Table 117. United States Branded Generics, by Application USD Million (2015-2020)
  • Table 118. United States Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 119. United States Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 120. Canada Branded Generics, by Type USD Million (2015-2020)
  • Table 121. Canada Branded Generics, by Application USD Million (2015-2020)
  • Table 122. Canada Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 123. Canada Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 124. Mexico Branded Generics, by Type USD Million (2015-2020)
  • Table 125. Mexico Branded Generics, by Application USD Million (2015-2020)
  • Table 126. Mexico Branded Generics, by Formulation Type USD Million (2015-2020)
  • Table 127. Mexico Branded Generics, by Distribution Channel USD Million (2015-2020)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Branded Generics: by Type(USD Million)
  • Table 139. Branded Generics Value Added Branded Generics , by Region USD Million (2021-2026)
  • Table 140. Branded Generics Trade (Brand) Named Generics , by Region USD Million (2021-2026)
  • Table 141. Branded Generics: by Application(USD Million)
  • Table 142. Branded Generics Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 143. Branded Generics Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 144. Branded Generics Online Pharmacies , by Region USD Million (2021-2026)
  • Table 145. Branded Generics Drug Stores , by Region USD Million (2021-2026)
  • Table 146. Branded Generics Others , by Region USD Million (2021-2026)
  • Table 147. Branded Generics: by Formulation Type(USD Million)
  • Table 148. Branded Generics Oral , by Region USD Million (2021-2026)
  • Table 149. Branded Generics Parenteral , by Region USD Million (2021-2026)
  • Table 150. Branded Generics Topical , by Region USD Million (2021-2026)
  • Table 151. Branded Generics Others , by Region USD Million (2021-2026)
  • Table 152. Branded Generics: by Distribution Channel(USD Million)
  • Table 153. Branded Generics Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 154. Branded Generics Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 155. Branded Generics Online Pharmacies , by Region USD Million (2021-2026)
  • Table 156. South America Branded Generics, by Country USD Million (2021-2026)
  • Table 157. South America Branded Generics, by Type USD Million (2021-2026)
  • Table 158. South America Branded Generics, by Application USD Million (2021-2026)
  • Table 159. South America Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 160. South America Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 161. Brazil Branded Generics, by Type USD Million (2021-2026)
  • Table 162. Brazil Branded Generics, by Application USD Million (2021-2026)
  • Table 163. Brazil Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 164. Brazil Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 165. Argentina Branded Generics, by Type USD Million (2021-2026)
  • Table 166. Argentina Branded Generics, by Application USD Million (2021-2026)
  • Table 167. Argentina Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 168. Argentina Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 169. Rest of South America Branded Generics, by Type USD Million (2021-2026)
  • Table 170. Rest of South America Branded Generics, by Application USD Million (2021-2026)
  • Table 171. Rest of South America Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 172. Rest of South America Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 173. Asia Pacific Branded Generics, by Country USD Million (2021-2026)
  • Table 174. Asia Pacific Branded Generics, by Type USD Million (2021-2026)
  • Table 175. Asia Pacific Branded Generics, by Application USD Million (2021-2026)
  • Table 176. Asia Pacific Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 177. Asia Pacific Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 178. China Branded Generics, by Type USD Million (2021-2026)
  • Table 179. China Branded Generics, by Application USD Million (2021-2026)
  • Table 180. China Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 181. China Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 182. Japan Branded Generics, by Type USD Million (2021-2026)
  • Table 183. Japan Branded Generics, by Application USD Million (2021-2026)
  • Table 184. Japan Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 185. Japan Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 186. India Branded Generics, by Type USD Million (2021-2026)
  • Table 187. India Branded Generics, by Application USD Million (2021-2026)
  • Table 188. India Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 189. India Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 190. South Korea Branded Generics, by Type USD Million (2021-2026)
  • Table 191. South Korea Branded Generics, by Application USD Million (2021-2026)
  • Table 192. South Korea Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 193. South Korea Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 194. Taiwan Branded Generics, by Type USD Million (2021-2026)
  • Table 195. Taiwan Branded Generics, by Application USD Million (2021-2026)
  • Table 196. Taiwan Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 197. Taiwan Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 198. Australia Branded Generics, by Type USD Million (2021-2026)
  • Table 199. Australia Branded Generics, by Application USD Million (2021-2026)
  • Table 200. Australia Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 201. Australia Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Branded Generics, by Type USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Branded Generics, by Application USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 206. Europe Branded Generics, by Country USD Million (2021-2026)
  • Table 207. Europe Branded Generics, by Type USD Million (2021-2026)
  • Table 208. Europe Branded Generics, by Application USD Million (2021-2026)
  • Table 209. Europe Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 210. Europe Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 211. Germany Branded Generics, by Type USD Million (2021-2026)
  • Table 212. Germany Branded Generics, by Application USD Million (2021-2026)
  • Table 213. Germany Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 214. Germany Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 215. France Branded Generics, by Type USD Million (2021-2026)
  • Table 216. France Branded Generics, by Application USD Million (2021-2026)
  • Table 217. France Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 218. France Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 219. Italy Branded Generics, by Type USD Million (2021-2026)
  • Table 220. Italy Branded Generics, by Application USD Million (2021-2026)
  • Table 221. Italy Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 222. Italy Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 223. United Kingdom Branded Generics, by Type USD Million (2021-2026)
  • Table 224. United Kingdom Branded Generics, by Application USD Million (2021-2026)
  • Table 225. United Kingdom Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 226. United Kingdom Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 227. Netherlands Branded Generics, by Type USD Million (2021-2026)
  • Table 228. Netherlands Branded Generics, by Application USD Million (2021-2026)
  • Table 229. Netherlands Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 230. Netherlands Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 231. Rest of Europe Branded Generics, by Type USD Million (2021-2026)
  • Table 232. Rest of Europe Branded Generics, by Application USD Million (2021-2026)
  • Table 233. Rest of Europe Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 234. Rest of Europe Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 235. MEA Branded Generics, by Country USD Million (2021-2026)
  • Table 236. MEA Branded Generics, by Type USD Million (2021-2026)
  • Table 237. MEA Branded Generics, by Application USD Million (2021-2026)
  • Table 238. MEA Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 239. MEA Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 240. Middle East Branded Generics, by Type USD Million (2021-2026)
  • Table 241. Middle East Branded Generics, by Application USD Million (2021-2026)
  • Table 242. Middle East Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 243. Middle East Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 244. Africa Branded Generics, by Type USD Million (2021-2026)
  • Table 245. Africa Branded Generics, by Application USD Million (2021-2026)
  • Table 246. Africa Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 247. Africa Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 248. North America Branded Generics, by Country USD Million (2021-2026)
  • Table 249. North America Branded Generics, by Type USD Million (2021-2026)
  • Table 250. North America Branded Generics, by Application USD Million (2021-2026)
  • Table 251. North America Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 252. North America Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 253. United States Branded Generics, by Type USD Million (2021-2026)
  • Table 254. United States Branded Generics, by Application USD Million (2021-2026)
  • Table 255. United States Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 256. United States Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 257. Canada Branded Generics, by Type USD Million (2021-2026)
  • Table 258. Canada Branded Generics, by Application USD Million (2021-2026)
  • Table 259. Canada Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 260. Canada Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 261. Mexico Branded Generics, by Type USD Million (2021-2026)
  • Table 262. Mexico Branded Generics, by Application USD Million (2021-2026)
  • Table 263. Mexico Branded Generics, by Formulation Type USD Million (2021-2026)
  • Table 264. Mexico Branded Generics, by Distribution Channel USD Million (2021-2026)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Branded Generics: by Type USD Million (2015-2020)
  • Figure 5. Global Branded Generics: by Application USD Million (2015-2020)
  • Figure 6. Global Branded Generics: by Formulation Type USD Million (2015-2020)
  • Figure 7. Global Branded Generics: by Distribution Channel USD Million (2015-2020)
  • Figure 8. South America Branded Generics Share (%), by Country
  • Figure 9. Asia Pacific Branded Generics Share (%), by Country
  • Figure 10. Europe Branded Generics Share (%), by Country
  • Figure 11. MEA Branded Generics Share (%), by Country
  • Figure 12. North America Branded Generics Share (%), by Country
  • Figure 13. Global Branded Generics share by Players 2020 (%)
  • Figure 14. Global Branded Generics share by Players (Top 3) 2020(%)
  • Figure 15. Global Branded Generics share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Mylan N.V (United States) Revenue, Net Income and Gross profit
  • Figure 18. Mylan N.V (United States) Revenue: by Geography 2020
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 21. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 26. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2020
  • Figure 27. Aspen Pharmacare (South Africa) Revenue, Net Income and Gross profit
  • Figure 28. Aspen Pharmacare (South Africa) Revenue: by Geography 2020
  • Figure 29. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 31. Valeant Pharmaceuticals International, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Valeant Pharmaceuticals International, Inc. (Canada) Revenue: by Geography 2020
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2020
  • Figure 35. GlaxoSmithKline Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline Pharmaceuticals (United Kingdom) Revenue: by Geography 2020
  • Figure 37. Global Branded Generics: by Type USD Million (2021-2026)
  • Figure 38. Global Branded Generics: by Application USD Million (2021-2026)
  • Figure 39. Global Branded Generics: by Formulation Type USD Million (2021-2026)
  • Figure 40. Global Branded Generics: by Distribution Channel USD Million (2021-2026)
  • Figure 41. South America Branded Generics Share (%), by Country
  • Figure 42. Asia Pacific Branded Generics Share (%), by Country
  • Figure 43. Europe Branded Generics Share (%), by Country
  • Figure 44. MEA Branded Generics Share (%), by Country
  • Figure 45. North America Branded Generics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Mylan N.V (United States)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Pfizer Inc. (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aspen Pharmacare (South Africa)
  • Abbott Laboratories (United States)
  • Valeant Pharmaceuticals International, Inc. (Canada)
  • Sanofi (France)
  • GlaxoSmithKline Pharmaceuticals (United Kingdom)
Select User Access Type

Key Highlights of Report


Apr 2021 204 Pages 77 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Branded Generics Quantitative research analysis
Global Branded Generics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Branded Generics Report?

Have a Query? Click Here

Other Related Reports

Insulin Glargine Comprehensive Study by Application (Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)), Forms (Liquid, Tablet, Syrup, Cream, Gel), Side Effect (Rash, Hives, Itching, Wheezing), Distribut...
$ 3800
Topical Pain Relief Comprehensive Study by Type (Prescription Pain Relief Products, Over-the-counter (OTC) Pain Relief Products), Application (Pets, Mammals, Farm Animals), Distribution Channel (Phar...
$ 3650
Atenolol Tablets Comprehensive Study by Application (Hypertension, Angina, Arrhythmias), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Prescription Mode (Prescript...
$ 3450
TB Vaccines Comprehensive Study by Type (Attenuated, Booster), Application (Hospitals, Clinical Labs, Pharmaceuticals), Distribution Channel (Online, Offline), Age Group (Pediatric, 16 Years – 35 Yea...
$ 3800
Atovaquone Comprehensive Study by Type (750mg, 5mL Oral suspension, 250mg/100mg, 62.5mg/25mg), Application (Ant malarial treatment, Pneumonia (Pneumocystis carinii), Others), Distribution Channel (On...
$ 3750
Terbinafine Hydrochloride Drug Comprehensive Study by Application (Athlete's Foot, Jock Itch, Ringworm, Others), Route of Administration (Topical, Oral), Duration of therapy (Fingernail onychomycosis...
$ 3450